Sandra Herrmann MD, FASN

@HerrmannMd

Nephrologist @MayoClinicNeph. Professor of Medicine @mayoclinic. Tweets are my own. #Onconephrology & Hypertension

Minnesota, USA mayo.edu/research/facul… Joined October 2018

726 Following 2.4K Followers 3.3K Posts

Latest posts 5

Pinned post

Sandra Herrmann MD, FASN @HerrmannMd Mar 9

TNF-α Blockade Mitigates Immune Checkpoint-Related Nephritis in a Humanized Mouse Model
⁦@JCI_insight⁩
@VictorCuenca3 @MayoClinicNeph
@onconephsociety
#onconephrology
First Immunocompetent chimeric 🐁 Model of ICI-AIN ! pubmed.ncbi.nlm.nih.gov/41785046/

pubmed.ncbi.nlm.nih.gov TNF-α blockade mitigates immune checkpoint-related nephritis in a humanized mouse model - PubMed Immune checkpoint inhibitors (ICIs) can cause immune-related adverse events (irAEs), with acute interstitial nephritis (ICI-AIN) being the most common irAE. While the exact mechanism remains unclear,...

Sandra Herrmann MD, FASN @HerrmannMd Oct 25

Another @ASNKidney Week in the books! Great to see everyone and reconnect. Safe travels. Until next year!

Sandra Herrmann MD, FASN @HerrmannMd Oct 24

Thank you, @LilianPalma412, for highlighting our study, just out in @NDTsocial! 🔥#KidneyWk @asnpublications

The only study looking at C5 inhibition with 100% of patients having biopsy-proven TMA!

@MayoClinicNeph @MBarbarini

Sandra Herrmann MD, FASN @HerrmannMd Oct 24

Congratulations to @MBarbarini, recipient of the @onconephsociety Travel Award for his presentation, “Longitudinal Biomarker Trends in Immune Checkpoint Inhibitor-Associated Acute Interstitial Nephritis,” at #KidneyWk 2026! 🎉 👏@ASNKidney

Sandra Herrmann MD, FASN @HerrmannMd Oct 23

👇🏽Hot off the press at @NDTsocial “C5 inhibition for the Renal TMA induced by cancer therapy”! Strong work by @MBarbarini and team @MayoClinicNeph ! @MayoCancerCare @MayoClinic 👇🏽free link onconephrology
academic.oup.com/ndt/advance-ar…

academic.oup.com C5 Inhibition for Anti-Cancer Therapy-Induced Renal Thrombotic Microangiopathy AbstractBackground and Hypothesis. Thrombotic microangiopathy (TMA) is increasingly recognized as a complication of both cancer and anti-cancer therapies.